Tandem Diabetes Care (TNDM)

Its flagship product is the t:slim X2 insulin pump, a compact rechargeable pump that can integrate with continuous glucose monitoring systems and automated insulin delivery algorithms. Tandem’s Control-IQ technology is designed to help adjust insulin delivery based on glucose readings, supporting tighter glucose management for many users. The company also markets infusion sets and cartridges, which create a recurring revenue stream because they must be replaced regularly.

Tandem is expanding its portfolio beyond the t:slim platform. The Mobi pump is a smaller device intended to give users more flexibility in how they wear and manage pump therapy. The company is also developing additional form factors, including tubeless or patch-style concepts, as it competes in a market where discretion, comfort, interoperability, and automation are important purchasing factors.

The United States accounts for the majority of Tandem’s revenue, with international sales coming primarily from developed healthcare markets. Its growth depends on diabetes prevalence, pump adoption, reimbursement coverage, physician and patient preference, regulatory approvals, and competition from companies offering insulin pumps, patch pumps, and smart pen technologies.